RT Journal Article
SR Electronic
T1 Clinical Characteristics of Hospitalized Patients with SARS-CoV-2 and Hepatitis B virus Co-infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.23.20040733
DO 10.1101/2020.03.23.20040733
A1 Chen, Xiaoping
A1 Jiang, Qunqun
A1 Ma, Zhiyong
A1 Ling, Jiaxin
A1 Hu, Wenjia
A1 Cao, Qian
A1 Mo, Pingzheng
A1 Yang, Rongrong
A1 Gao, Shicheng
A1 Gui, Xien
A1 Xiong, Yong
A1 Li, Jinlin
A1 Zhang, Yongxi
YR 2020
UL http://medrxiv.org/content/early/2020/03/30/2020.03.23.20040733.abstract
AB Background & Aims The coronavirus disease 2019 (COIVD-19) caused by SARS-CoV-2 has been characterized as a pandemic, which causes a serious public health challenge in the world. A very large group of patients infected by HBV has been reported worldwide, especially in China. In order to answer whether specific treatment strategy on the patients coinfected with HBV and SARS-CoV-2, it requires profound understanding of the clinical characteristics on those patients. However, the impacts of SARS-CoV-2 infection on HBV patients remain largely unknown.Approach & Results In this retrospective investigation, we included 123 COVID-19 patients admitted to Zhongnan Hospital of Wuhan University, Wuhan, China, from January 5 to March 7, 2020. All enrolled patients are the laboratory confirmed COVID-19 pneumonia cases according to the criteria reported previously. A total of 123 patients were analyzed for their Clinical records, laboratory results including the diagnosis of HBV infection and liver function. Among 123 confirmed COVID-19 patients, the mean age was 51 years old and 59.3% were females (73/123). Fifteen were previously HBV infected patients, 66.7% of them were males (10/15), patients with HBV infection appeared to have a higher incidence of liver cirrhosis and an increased level of total bilirubin. Seven (46.7%) patients with HBV infection were defined as severe cases, while the severity rate was 24.1% for the patients without HBV infection (26/108). The mortality of patients with HBV infection was 13.3% (2/15) compared to 2.8% (3/108) for the patients without HBV infection.Conclusions SARS-CoV-2 infection may cause Live function damage in COVID-19 cases and the patients with HBV infection are likely to have more severe disease outcome.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund, grant number znpy2018007. The funders had no role in study design, data collection or analysis, decision to publish or preparation of the manuscript. The authors declared no competing interests.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are availability.COVID-19Coronavirus Disease-2019HBVHepatitis B virus